Everolimus Stent in Patients With Coronary Artery Disease (CAD)
Launched by SAN GIUSEPPE MOSCATI HOSPITAL · Aug 16, 2010
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-elu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients with coronary artery disease eligible for percutaneous coronary intervention (PCI)
- Exclusion Criteria:
- • Contraindication to dual antiplatelet therapy for 12 months
- • Known allergy to sirolimus or everolimus
- • Major surgical procedure planned within 1 month
- • History, symptoms, or findings suggestive of aortic dissection.
- • Participation in other trials
- • Pregnancy
About San Giuseppe Moscati Hospital
San Giuseppe Moscati Hospital is a renowned medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence in patient care, the hospital integrates cutting-edge technology and evidence-based practices to explore new therapeutic options across various medical fields. The institution fosters collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic partners, ensuring a rigorous approach to clinical research that prioritizes patient safety and ethical standards. By participating in clinical trials, San Giuseppe Moscati Hospital aims to contribute to the development of effective treatments and enhance the overall quality of care for its patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Avellino, , Italy
Patients applied
Trial Officials
EMILIO DI LORENZO, MD PhD
Principal Investigator
DIVISION OF CARDIOLOGY AORN MOSCATI AVELLINO ITALY
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials